<DOC>
	<DOCNO>NCT00983099</DOCNO>
	<brief_summary>Part 1 ( single dose ) Primary parameter - Area plasma concentration curve zero infinity [ AUC0-inf ] observe maximum plasma concentration [ Cmax ] Japanese Caucasian subject dose group - If least 20 % Japanese Caucasian subject area plasma concentration curve extrapolation [ AUCextrap % ] &gt; 20 % relative AUC0-inf one dose group area plasma concentration curve zero last measurable concentration [ AUC0- tz ] become primary parameter Japanese Caucasian subject dose group . In case AUC0-tau become secondary parameter Secondary parameter derive value statistical analysis - Dose proportionality linearity Japanese subject - Ratios ( Japanese vs. Caucasian subject ) AUC0-∞ Cmax dose group - Dose normalized AUC [ AUC0-inf , norm ] , dose normalize Cmax [ Cmax , norm ] , AUC0- tz , time occurrence Cmax [ tmax ] , apparent terminal half life [ t½ ] , mean residence time [ MRT ] , apparent ( oral ) total plasma clearance [ CLtot/f ] , apparent volume distribution terminal disposition phase [ Vz/f ] , AUCextrap % , apparent terminal disposition rate constant [ λz ] , weight correct AUC0-inf , weight correct AUC0-tz , weight correct Cmax , weight correct CLtot/f , cumulative amount excrete Neramexane urine [ Ae0-tz ] , fraction orally administrate drug excrete urine [ fe/f ] , renal clearance [ CLR ] apparent non-renal clearance [ CLNR/f ] - Safety tolerability Other parameter - Pharmacogenetics - Amount N-OH Neramexane excrete urine [ Ae0-tz ] validate method available time analysis - Metabolite determination ( N-OH Neramexane ) plasma urine , optional ( may analyze evaluate validated method available time analysis ) - Endogenous creatinine clearance [ CLCR ] , amount excrete creatinine urine per hour [ AeCR , hr ] - Evaluation metabolite describe detail Statistical Analysis Plan</brief_summary>
	<brief_title>Evaluation Pharmacokinetics , Safety Tolerability Single Multiple Oral Doses Neramexane Mesylate Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject Caucasian ( Part 1 ) Japanese origin Japanese subject must Japanese passport , Japanese grandparent parent live outside Japan 5 year Aged 20 55 year ( inclusive ) Body weight 50 90 kg ( inclusive ) BMI range 18.0 28.0 kg/m2 ( inclusive ) Japanese female may body weight least 45 kg ( inclusive ) BMI range 17.0 28.0 kg/m2 ( inclusive ) Females must negative urine pregnancy test screen Day 1 Part 1 Day 1 Part 2 Subjects must willing use one follow method contraception first dose trial medication completion followup procedure . All subject must agree use condom spermicide . Male subject without vasectomy ( documentation azoospermia ) must assure female partner use another form contraception non hormonal IUD , diaphragm . Female subject childbearing potential must agree use effective method birth control sexual abstinence , vasectomise partner , non hormonal IUDs double contraception method ( e.g. , condom spermicide cream ) Screening one month last application study drug . Willing able give write informed consent inform requirement restriction study Subjects take part drug administration phase single dose part exclude participation multiple dose part study vice versa Any clinically relevant find medical history , physical examination affect subject 's safety study objectives Any disease condition , could influence physiological absorption , distribution metabolic turnover ( e.g . endocrine disease , febrile condition , severe infection , acute inflammation , chronic diarrhoea , chronic vomiting , gastrointestinal disease surgery gastrointestinal tract , include cholecystectomy ) ; appendectomy old 6 month allow Prior history present evidence clinically significant metabolic , renal , hepatic , pulmonary cardiovascular disease , CNS disorder disturbance bleed ( hemorrhagic diathesis ) , diagnosis malignancy , polyneuropathy psychiatric disorder , organ transplantation Any clinically relevant abnormal laboratory value ( haematology , clinical chemistry , urinalysis ) laboratory value discretion investigator Merz scientific expert might affect subject 's safety study objective Positive serology human immunodeficiency virus [ HIV ] ( HIV1/HIV2 antibody ) , hepatitis B surface antigen [ HBsAg ] , antibodies hepatitis C virus [ antiHCV ] Clinically relevant abnormality 12lead ECG discretion investigator Merz scientific expert might affect study objective Presence history clinically relevant allergy know suspected hypersensitivity Neramexane , Memantine Amantadine and/or study medication excipients quinine hydrochloride ( slight seasonal hay fever allow long season meet study period ) History alcohol drug dependence Alcohol consumption average 40 g alcohol ( 4 unit ) daily ( 28 unit per week ) within last year male 20 g ( 2 unit ) daily within last year female Regular caffeine consumption average 5 cup coffee equivalent ( 500mg caffeine ) per day within last year Smoking 5 cigarette per day equivalent ( use snuff , nicotine replacement chew tobacco ) Refusal inability eat meal provide clinic ( e.g . vegetarian ) Nursing mother Woman planning pregnancy course trial Evidence suspicion subject might comply study directive and/or he/she reliable trustworthy Evidence suspicion subject willing unable understand information give him/her part inform consent , particular regard risk discomfort he/she would agree exposed Subjects imprison lawfully kept institution Employees direct relatives employee CRO Merz Pharmaceuticals Systolic blood pressure &lt; 90 mm Hg &gt; 140 mm Hg diastolic blood pressure &lt; 50 mm Hg &gt; 95 mm Hg supine position Pulse rate &lt; 45 &gt; 100 beat per minute [ bpm ] Use prescribe drug 4 week prior first administration IMP Regular use overthecounter [ OTC ] drug ( except paracetamol , maximum 1 g/day ) 4 week prior first administration IMP least 10 half life , whichever longer Occasional use OTC drug ( except paracetamol , maximum 1 g/day ) 2 week prior ( first ) administration IMP Females take hormonal contraceptive Participation another clinical study IMP within 2 month prior first administration IMP History blood loss donation blood plasma exceed 450 ml within last 3 month first administration IMP Acute illness past 14 day administration IMP ( Day 1 ) Fever ( oral &gt; 37.5 °Celsius 99.5 °Fahrenheit , respectively ) last 8 day Day 1 report history Day 1 Alcohol intake within last 48 hour prior ( first ) administration IMP positive alcohol breath test Screening Day1 Part 1 Day 1 Part 2 Intake recreational drug within last 4 week prior first administration IMP Day 1 positive urine test drug abuse screening , Day 1 Part 1 Day 1 Part 2 Consumption xanthine contain food beverage within last 48 hour prior first administration IMP Consumption herbs/fruits influence pharmacokinetics St. Johns wort , grapefruits grapefruit juice within last 72 hour prior first administration IMP</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>